Dulaglutide
Trulicity
- Made by
- Eli Lilly
- FDA approval
- September 2014
- Indication
- Type 2 diabetes
- Dose ceiling
- 4.5 mg weekly
- Typical loss
- ~3–4% body weight at 6–12 months at 4.5 mg
- Cash list
- $890–$1,000 list
Both are GLP-1 receptor agonists. Beyond that they differ in molecule, FDA indication, dose ceiling, and — most importantly to most people reading this — what the scale actually does over the long run.
Dulaglutide
Tirzepatide
Lilly's old GLP-1 vs. Lilly's dual agonist. Mounjaro produces dramatically more weight loss and A1c reduction. Trulicity remains relevant only for patients prioritizing injection comfort or facing coverage barriers to tirzepatide — its hidden-needle pen is widely considered the gentlest device in the class.
Molecule
TrulicityDulaglutide
MounjaroTirzepatide
Receptor(s)
TrulicityGLP-1
MounjaroGIP + GLP-1 (dual agonist)
Manufacturer
TrulicityEli Lilly
MounjaroEli Lilly
FDA approval
TrulicitySeptember 2014
MounjaroMay 2022
Indication
TrulicityType 2 diabetes
MounjaroType 2 diabetes (with HFpEF and OSA indications added 2024)
Delivery
TrulicitySubcutaneous injection, once weekly
MounjaroSubcutaneous injection, once weekly
Dose ceiling
Trulicity4.5 mg weekly
Mounjaro15 mg weekly
Titration
TrulicityMaintenance from 0.75 mg; titration optional
Mounjaro4 weeks per step
Typical loss
Trulicity~3–4% body weight at 6–12 months at 4.5 mg
Mounjaro~9–13% body weight at 1 year in T2D patients (SURPASS), ~22% off-label in non-diabetics at 15 mg
Cash list
Trulicity$890–$1,000 list
Mounjaro$1,070–$1,180 list
On patent until
Trulicity2027 (with composition extensions)
Mounjaro2036 (US composition of matter; formulation patents to ~2039)
No journeys yet — be the first.